IVEVF News and Press, Inventiva SA From 03/05/21

The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVEVF) Investor Presentation - Slideshow

Investment Thesis Formulating the launch plans well ahead of the approval, Intercept Pharmaceuticals, Inc. ( ICPT ) caught completely off guard when the FDA refused to sign off OCA, a Intercept’s candidate for liver fibrosis in NASH. The agency, however, hasn’t completely ...

Introduction In March, I wrote an article about Genfit (NASDAQ: GNFT ) and the potential of its lead drug candidate Elafibranor in NASH. In my analysis, I underlined the huge upward potential but also underpinned the binary characteristic of the investment case. My recommendation was to ...

French biopharma Inventiva ( OTCPK:IVEVF ) has emerged as a new player in the pursuit of a treatment for nonalcoholic steatohepatitis (NASH). More news on: Inventiva S.A., Genfit SA, CymaBay Therapeutics, Inc., Healthcare stocks news, Read more ...

Introduction It is remarkable how few articles have been published about Genfit ( GNFT) lately on Seeking Alpha. The last articles dated from June and August last year. This is quite remarkable since the company is nearing its make-or-break moment and indicates that investors’ ...